Theriva Biologics (TOVX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$3.2M

Net income growth (year over year)

+75.36%

Net margin

—

Return on equity

−115.11%

EPS (trailing twelve months)

$1.44

Book value per share

$0.27

P/E (trailing twelve months)

—

Price to book

0.81

Debt to assets

65.04%

Payout ratio

—

Dividend yield

—

Company profile

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

• How do I buy stock in Theriva Biologics (TOVX)?

  TOVX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.